Cortexin vs DSIP.

Cortexin is a low-molecular-weight polypeptide preparation extracted from the cerebral cortex of cattle and calves. It contains a mixture of short water-soluble peptides (roughly 1 to 10 kDa), amino acids and trace elements, and is supplied as a lyophilized powder reconstituted for intramuscular injection. Developed and marketed primarily in Russia by GEROPHARM, it is positioned as a neurotrophic and neuroprotective agent. It is used clinically within Russia and several neighboring countries for a range of neurological conditions.

DSIP (Delta Sleep-Inducing Peptide) is a small endogenous nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), molecular weight roughly 850 Da. It was first isolated in 1974 by Schoenenberger, Monnier and colleagues in Switzerland from the cerebral venous blood of rabbits placed in an electrically induced state of slow-wave (delta) sleep, and named for that apparent sleep-promoting property. DSIP-like immunoreactive material has since been detected in various mammalian tissues and human fluids (including breast milk), but it remains a biochemical "riddle": no gene, precursor protein, or specific receptor for it has been definitively identified.

Like other brain-tissue peptide preparations, Cortexin is a complex mixture, so its activity is attributed to the combined effect of many peptide-protein interactions rather than a single molecular target. Proposed mechanisms include support of neuronal energy metabolism, antioxidant and anti-apoptotic effects, and modulation of neurotrophic factors and neurotransmitter systems such as GABA and dopamine. Its low-molecular-weight peptides are claimed to cross the blood-brain barrier. These mechanisms are largely inferred from preclinical models.

DSIP has no single confirmed receptor or signaling pathway; its mechanism remains genuinely unresolved despite decades of study. Reported preclinical interactions are diffuse and concentration-dependent, including modulation of NMDA-receptor activity, effects on glucocorticoid/stress-axis regulation, and engagement of MAPK signaling cascades, along with proposed influences on GABAergic, opioid/enkephalin, and somatostatin systems. It does not behave like a classical hypnotic acting at a defined target; instead it has been framed as a neuromodulator or "homeostatic" regulator with dose- and timing-dependent, sometimes bidirectional, effects on arousal. Its very short circulating half-life (on the order of minutes) further complicates any straightforward receptor-occupancy mechanism.

The evidence base for Cortexin comes predominantly from Russian-language studies and preclinical models, with limited independent Western validation. A recent preclinical study (Kurkin et al., Biomedicines 2025) reported neurotropic effects in rat models of toxic and traumatic developmental delay. Clinical use is widespread in Russia across pediatric neurology, stroke rehabilitation and cognitive disorders, but large, blinded, international randomized trials indexed in mainstream databases are scarce. As a result, Cortexin has not been subjected to the RCT and Cochrane-level scrutiny applied to Cerebrolysin. Its efficacy claims should therefore be read with caution. The human literature is dominated by multicenter observational programs rather than randomized comparisons: the CORNELia program in chronic cerebrovascular disease with cognitive impairment and the CORTEX program in post-COVID neurological complaints are both described as observational, meaning they lack a concurrent randomized control arm, blinding, and placebo control, so improvement over time cannot be separated from natural recovery, regression to the mean or expectation effects. Comparative studies do exist within the same national literature, for example a comparison with another peptide preparation in the early recovery period after ischaemic stroke, but these are typically single-country, modest in size and published in one journal, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, closely associated with the domestic market for the drug. Preclinical support includes rodent work on antioxidant effects in chronic cerebrovascular insufficiency and a cell-culture study reporting protection of cultured rat sensory neurons from high-glucose injury. Nearly all of this literature originates in the country where the product is registered and marketed, and the manufacturer's involvement in the observational programs is a relevant consideration. What is missing is specific: no independent multinational randomized trial, no Cochrane or comparable systematic review, no published characterization of which peptides in the extract are active, and no external regulatory assessment of the manufacturing and potency standards. Cortexin sits alongside thymalin, vilon and epitalon in resting on single-country literature, while Cerebrolysin, despite its own unresolved questions, has at least been tested in independently reviewed randomized trials.

Human data exist but are old, small, and mixed. Small studies from the early 1980s (e.g., Schneider-Helmert and colleagues, Experientia 1981; Int J Clin Pharmacol Ther Toxicol 1981) reported acute and delayed improvements in sleep efficiency, latency and continuity in insomniac and normal subjects after intravenous DSIP, with good tolerability. However, a later double-blind matched-pairs study in 16 chronic insomniacs (Neuropsychobiology, 1992) found higher sleep efficiency and shorter latency yet concluded short-term DSIP is "not likely to be of major therapeutic benefit." A 1984 clinical trial (European Neurology) and a pilot study in chronic pain also reported effects, and a 2009 anaesthesia study (European Journal of Anaesthesiology) found DSIP altered bispectral index/EEG as an isoflurane adjunct. A 2006 Journal of Neurochemistry review explicitly calls DSIP "a still unresolved riddle," underscoring that no modern, adequately powered, registration-quality trial has confirmed a clinical sleep benefit.

Cortexin is generally described in its clinical literature as well tolerated when given intramuscularly, with hypersensitivity and allergic reactions being the main labeled concern. As a parenteral bovine-derived biological, theoretical risks include allergic reactions and injection-site effects, and the same category concerns apply that attach to any animal-tissue extract given by injection: immunogenicity on repeated courses, dependence on the source herd and purification process for freedom from adventitious agents, and the practical difficulty of proving batch equivalence for a mixture whose active constituents are not defined. Independent long-term safety data from outside its region of use are limited, and the observational design of most human reports means adverse events were collected without a comparator, so background rates cannot be separated from drug-related events. Use in children, which is common in the Russian pediatric neurology setting, has not been evaluated in independently reviewed controlled trials, and pediatric exposure is precisely the situation where an external safety assessment would ordinarily be required. Product acquired outside licensed pharmacy channels carries additional contamination and counterfeit risk, since injectables demand verified sterility and endotoxin control that unregulated supply cannot demonstrate. A trial-grade safety evaluation would include prospective adverse-event capture against a control arm, hypersensitivity monitoring, hepatic and renal laboratory follow-up, and anti-drug antibody testing on repeat courses. It is a prescription clinical product, not a dietary supplement.

In the small historical human studies DSIP was generally described as well tolerated with few reported acute side effects, including reports of no daytime sedation hangover. However, these trials were tiny, short-term, and decades old, so the safety database is thin and there is essentially no modern controlled long-term safety, immunogenicity, or chronic-exposure data. Material sold for "research" is unregulated, of unverified purity and identity, and not produced to pharmaceutical standards, which introduces contamination and mislabeling risks independent of the peptide itself. Long-term effects, drug interactions, and effects in any specific population remain unknown.

Cortexin is not FDA-approved and is not marketed in the United States or the European Union. It is a registered prescription medicine in Russia and several post-Soviet states. This summary is educational and includes no dosing information.

DSIP is not approved by the FDA (or, to public knowledge, any major regulator) as a drug for sleep or any other indication; it has only ever been an investigational/experimental compound and is currently sold as a research-use-only chemical. It is not a WADA-prohibited substance by name, but it is not a legitimate, quality-controlled medicine.